The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) fell 6% in the afternoon session after investor concerns were sparked by a disappointing financial outlook from peer DexCom.

Continuous glucose monitors — the tiny sensors once reserved for people with diabetes — are now appearing on the arms of ...

DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported ...

Among 91 women, those who used a closed-loop insulin delivery system spent an average of 65.4% of time in pregnancy-specific ...

The finding could lead to the development of better drugs for infections like the flu, autoimmune diseases and more.